Chimeric antigen receptor (CAR) T cells, T cells that have been genetically engineered to
express a receptor that recognizes a specific antigen, have given rise to breakthroughs in …

Malignant brain tumours are complex ecosystems containing neoplastic and stromal
components that generate adaptive and evolutionarily driven aberrant tissues in the central …

Chimeric antigen receptor (CAR) T cell therapy is revolutionizing cancer immunotherapy for
patients with B cell malignancies and is now being developed for solid tumors and chronic …

Treatment of solid cancers with chimeric antigen receptor (CAR) T cells is plagued by the
lack of ideal target antigens that are both absolutely tumor specific and homogeneously …

Chimeric antigen receptor (CAR) T-cell therapy targeting solid tumors has stagnated as a
result of tumor heterogeneity, immunosuppressive microenvironments, and inadequate …

Importance Glioblastoma is an incurable tumor, and the therapeutic options for patients are
limited. Objective To determine whether the systemic administration of HER2-specific …

In preclinical models of glioblastoma, antigen escape variants can lead to tumor recurrence
after treatment with CAR T cells that are redirected to single tumor antigens. Given the …

Background Glioblastoma (GBM) is the most common primary malignant brain cancer, and
is currently incurable. Chimeric antigen receptor (CAR) T cells have shown promise in GBM …

Gliomas are one of the most common types of primary brain tumors and have remained
particularly challenging to treat. This review illustrates a multidisciplinary approach to the …

Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumor in adults. Current treatment options typically consist of surgery followed by …